




RealRate

PHARMACEUTICAL 2020

ZOGENIX INC.
Rank 297 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

ZOGENIX INC.
Rank 297 of 362

The relative strengths and weaknesses of ZOGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ZOGENIX INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 79% points. The greatest weakness of ZOGENIX INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 306% points.

The company's Economic Capital Ratio, given in the ranking table, is -491%, being 188% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	287,239
Cost of Goods Sold	0
Intangible Assets	6,234
Liabilities, Current	95,389
Liabilities, Non-Current	18,177
Other Assets	111,353
Other Compr. Net Income	376
Other Expenses	257,038
Other Liabilities	55,625
Other Net Income	10,318
Property and Equipment	9,424
Research and Development	115,639
Revenues	3,648
Selling, General and Administrative Expense	60,792

Output Variable	Value in 1000 USD
Assets	414,250
Liabilities	169,191
Expenses	433,469
Stockholders Equity	245,059
Net Income	-419,503
Comprehensive Net Income	-419,315
Economic Capital Ratio	-491%

